Effect of the Administration of L-Carnitine on Body Weight in Women in Crossfit Training

University of Guadalajara

Status and phase: Unknown; Phase 2

Conditions: Body Weight Changes

Treatments: Dietary Supplement: Sucralose; Drug: L-Carnitine

Study type: Interventional

Funder types: Other

Identifiers

NCT03436277

LC-CUT-DMHC

Details and patient eligibility

About

The L-carnitine has demonstrated effects in the treatment of obesity mainly promoting the fat degradation during exercise.

Full description

A randomized, double-blind, placebo-controlled clinical trial will be carry out in 24 woman with body mass index ≥ 25 to 29.9 kg/m2. The patients will receive 1.5 g of L-Carnitine deluded in 250 ml of water or placebo before crossfit training, 5 times a week for 8 weeks. Before and after intervention the investigators evaluate: The body composition (body fat, lean body mass), arm muscle circumference, waist circumference, body weight and body mass index.

Enrollment: 24 estimated patients

Sex: Female

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Volunteers who practice crossfit regularly (who have 3 months prior to the beginning of the study practicing crossfit).
• Volunteers with a body mass index equal to or greater than 25 Kg/m2.
• Volunteers who do not have allergies to L-Carnitine or any of its components.
• Informed consent signed
• Women with a recommendation of nutrition two weeks prior to the start of the study.
• Body weight stable the last 3 months.

Exclusion criteria

• Volunteers with pathologies such as diabetes, hypertension, metabolic syndrome and allergies.
• Women with confirmed or suspected pregnancy.
• Women under lactation and/or puerperium.
• Hypersensibilility to L-Carnitine or Sucralose.
• Kown of renal, hepatic or thyroid deseased.
• Current or previous treatment diet (3 months before inclusion to the study).
• Current pharmacological treatment for loose body weight or 3 months before inclusion to the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

24 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Sucralose 1,5 g

Treatment:

Dietary Supplement: Sucralose

L-Carnitine

Experimental group

Description:

L- Carnitine 1,5 g

Treatment:

Drug: L-Carnitine